Dec 08, 2020 – As published on Imazpress
Torskal approaches the start of phase 1 clinical trials for the validation of Nanotheranostic, a treatment for skin cancer using near infrared (IR) radiation-induced plasmonic phototherapy, the Clinifutur group, founded by Dr. Michel Deleflie, has just acquired a stake in the start-up to support it in a long-term partnership.
Clinifutur had already intervened to support the research of the Torskal team on the evaluation of gold nanoparticles (NP) as – potentiator of radiotherapy (radioenhancer) and as mediator of hyperthermia by plasmonic phototherapy. These gold nanoparticles are obtained by using the bio-reducing potential of plant extracts from Réunion’s biodiversity.
Anne-Laure Morel, founding president of Torskal, Ph.D. in the physical chemistry of materials and a master’s degree in structural biochemistry, specifies that these unprecedented trials will be conducted at the Clinique Sainte-Clotilde (CSC), in association with Drs. Mickaël Bègue and Youssef Slama, respectively radiation oncologist and head of the radiophysics unit at the CSC, and Antoine Bertolotti, dermatologist at the CHU de Saint-Pierre. In metropolitan France, parallel clinical trials will be conducted in collaboration with a public hospital.